

Nonopioid Analgesics:

The Selection and Use of Adjuvant Therapies Thomas B. Gregory, PharmD, BCPS, FASPE, CPE

1

Disclosures

Nothing to disclose

Painweek.

2

Objectives

Describe where adjuvant analgesics act in the pain pathway and their differences in mechanism of action

· Compare risks and benefits for different adjuvant analgesics

Choose an adjuvant analgesic based on current guidelines and/or evidence-based medicine as well as individual patient factors

Are opioid overdoses still a concern? • Opioid overdoses increased 30 percent from July 2016 through September 2017 in 45 states FORUSE L Quarterly Program, July 2015- The Midwestern region saw opioid overdoses increase 70 percent from July 2016 through September 2017 Opioid overdoses in large cities increase by 54% in 16 states Vivolo-Kantor, MM, Seth, P. Gladden, RM, et al. Vital Signs: Trends in Emergency Department Visits for Suspected Opioid Overdoses-United States, July 2016-September 2017. Centers for Disease Control and Prevention Painweek.

4

Risk Factors for Opioid Overdose or Addiction

Risk factors for overdose Daily dose > 100 MEDD

- Long-acting (LA) or extended-release (ER) formulation

Combination with benzodiazepines

- Long-term use (> 3 months)
 Period shortly after initiation of LA/ER formulation
 - Substance use disorder History of overdose

Risk factors for addiction


 Sleep disordered breathing Renal/hepatic impairment

Volkow NJ et al. NEJM.2016;374:1253-1263. MEDD = morphine equivalent daily dose


Age > 65 years

Depression

Painweek.









7



Painweek.









Celecoxib & Cardiovascular (CV) Safety

 <u>Clinical question</u>: How does the CV safety of celecoxib, a COX-2 selective NSAID, compare to that of a nonselective NSAID, such as ibuprofen or naproxen?

 Primary composite outcome of CV death (including hemorrhagic death), nonfatal MI, or nonfatal stroke

• Mean treatment duration of 20.3 ± 16.0 months and a mean follow-up period of 34.1 ± 13.4 months

 In regards to the primary outcome, celecoxib was found to be noninferior to both ibuprofen and naproxen
 Disk of Counter our construction of the primary of the p

N Engl J Med 2016; :2519-2529.

1. Am J Gastroenterol. 2009;104:728-738. 2. JMCP. 2013;19(9):S3-S19. 3. Circulation. 2007;115:1634-1642.

Bisk of Givents was *significantly lower* with celecoxib compared to both ibuprofen and naproxen
 Study funded by Pfizer

Painweek.

11

NSAIDs and GI Adverse Effects

•Strategies to prevent gastric mucosal damage in chronic NSAID users:

–Proton pump inhibitor (PPI)

-Histamine-2 receptor antagonist (H2RA)

-Use of COX-2 selective NSAID

• Risk factors for NSAID-related GI toxicity:

-History of peptic ulcer disease or upper GI bleed

-≥65 years old

-Presence of comorbidities such as rheumatoid arthritis

-Concomitant use of anticoagulants, aspirin or corticosteroids


Painweek.

Diclofenac so	dium 1% ael
-Dosing:	
•Upper ex one joint	tremity (hands, elbows, wrists): 2g applied QID up to 8g on any
 Lower ex any one j 	tremity (knees, ankles, and feet): 4g applied QID up to 16g on oint
Diclofenac ep	olamine 1.3% patch
-1 patch app	lied BID to the most painful area
	carry the same boxed warnings but are proposed to have a e safety profile than oral NSAIDs

13

Corticosteroids

Painweek.





Glucocorticoids

 Mechanism of action leads to a decrease in production of heat shock proteins intracellularly leading to a decrease inflammation Multiple routes of administration

Glucocorticoid

- -Oral
- -Parenteral
 - ۰IV
 - •IM depot

Intraarticular

Painweek.

16

Glucocorticoids (cont'd)

Caution should be exercised in patients
with the following conditions
 —Diabetes

-Psychiatric history

-Heart failure

-Adrenal suppression •Taper needed when therapy exceeds 10 to 14 days

-Immunocompromised

Painweek.





Anticonvulsants Painweek.

19

Anticonvulsants Gabapentin & Pregabalin

 \bullet Structurally related to GABA but it does not bind to GABA_A or GABA_B receptors or influence the degradation or uptake of GABA -Binds to the $\alpha_2\text{-}\delta$ subunit of voltage-gated Ca^{2*} channels in CNS and peripheral nerves


Reduces the Ca²⁺-dependent release of pro-nociceptive neurotransmitters, possibly by modulation of Ca²⁺ channel function

Pregabalin may also interact with descending noradrenergic and

serotonergic pathways in the brainstem

Painweek.

J Clin Psychiatry. 2007 Mar;68(3):483-4.





Anticonvulsants

Gabapentin

- Initial dose: 100 mg to 300 mg by mouth up to 3 times daily
- . Increase dose based on response and tolerability to a maximum total daily dose of 3600 mg

https://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6961 accessed 1.10.2020

eve/docid/patch_f/152621 accessed 1.10.2020

- Renal dose adjustment required • NO hepatic adjustment needed
- -Gabapentin is not metabolized by hepatic enzymes
- Most common adverse effects:
- -Dizziness and drowsiness (approx. 20%) -Ataxia
- -Fatigue

Painweek.

22

Anticonvulsants (cont'd)

Pregabalin

- Initial dose: 25 mg to 150 mg by mouth once or twice a day
- Increase dose in 1 week based on tolerability to a maximum daily dose of 450 mg -Doses up to 600 mg have been evaluated with no significant additional benefit Renal dose adjustment required

ne.lexi.com/lco/action/doc/

- NO hepatic adjustment needed
- -Pregabalin is minimally metabolized by hepatic enzymes Most common adverse effects:

https://

-Dizziness and somnolence

-Peripheral edema

Painweek.

23



Carbamazepine

- Drug of choice for trigeminal neuralgia May require titration of dose to maximum of 1200 mg/day
- -Consider obtaining baseline CBC and LFTs Consider periodic monitoring of CBC and LFTs thereafter

Oxcarbazepine

- -Better tolerability compared to carbamazepine - Titration begins at 150 mg twice daily to a maximum dose of 1800 mg/day
- Patients allergic to carbamazepine should also avoid oxcarbazepine, 25% allergic cross-reactivity
 - Hooten M, et al. Institute for Clinical Systems Improvement. Pain: Assessment, Non Opioid Treatment Approaches and Opioid Management. Updated September 2016.
 Update on neuropathic pain treatment for trigeminal neuralgia. Neuroscience, 20.2:107-14 2015.

Anticonvulsants: Alternative Options (cont'd)

- Lamotrigine (off-label indication)

- Data support (unreader indication)
 Data supports use in refractory trigeminal neuralgia, central poststroke pain, SCI pain with
 incomplete cord lesion and brush-induced allodynia, HIV-associated neuropathy in patients on
 antiretroviral therapy, and diabetic neuropathy
 -Most effective at doese between 200-400 mg/day
 -Note: follow strict titration schedule to reduce the risk of serious skin reactions
- Immune response?


Topiramate (off-label indication)

 Data supports use in diabetic neuropathy, refractory trigeminal neuralgia, and for migraine prophylaxis
 Dosing generally ranges from 50-100 mg/day
 Dosing over 200 mg is generally side-effect limiting

Neurol Sci (2006) 27:S183–S189.
 R.H. Dworkin et al. / Pain 132 (2007) 237–251.

Painweek.

25



26

Antidepressants

Painweek.

Tricyclic Antidepressants (TCAs)

Initial dosing of TCAs


• Nortriptyline 10 mg at bedtime (off-label indication) • Desipramine 25 mg at bedtime (off-label indication)


Amitriptyline 10-25 mg at bedtime (off-label indication)
 –Use with caution in BPH, glaucoma, cardiac disease, and those at risk for suicide

Lancet Neurol 2015; 162–73.

Painweek.

28







TCAs-Cardiovascular Risk

- Orthostatic/postural hypotension
 - -Alpha adrenergic blockade (even at low doses)
- Slowed cardiac conduction, tachycardia, ventricular fibrillation, heart block, and ventricular premature complexes (similar to Class Ia AA) Sudden cardiac death (unclear association with QTc prolongation)
- -Avoid doses > 100 mg/day amitriptyline equivalents
- Avoid in those with cardiovascular disease or established conduction abnormalities
- Baseline ECG recommended by some in those > 40 years of age (> 50 years of age based on APA Depression Guidelines²)

Ray WA, et al. *Oin Pharmacol Ther*. 2004;75:234-241.
 https://psychiatryonline.org/pb/assets/raw/sitewide/practice_g uidelines/guidelines/mdd.pdf accessed 1.10.2020

- Routine ECG monitoring not recommended unless CV symptoms arise

Painweek.

31

TCAs-Behavioral Health Risks

Abrupt discontinuation

-Withdrawal symptoms (GI, malaise, chills, rhinitis, and myalgias) -Rebound depression

Increased suicidality vs overdose toxicity

- -Boxed warning for children, adolescents, young adults (18-24 years of age)
- -Cardiac (QTc) and anticholinergic toxicity at doses as little
- as 10 x prescribed

Labbare, LA, Fave, M. Rosenbaum, JF, et al. Drugs for the treatment of depression. In: Handbook of Psychiatric Drug Therapy feb A of Lippoincot Williams & William, Psychiatrophan 2010.
 Dalai A et al. J Clin Psychopharmocology. 1998;18:343-344.
 Fryne MA, et al. Am J Psychotry. 2009;16:61:61-12.
 Van Schweng, D. et al. And Clin Psychotry. 1997;8:560-555.

Painweek.

32

SNRI Venlafaxine (off label)

Initial dose: 37.5 mg to 75 mg ER by mouth Increase dose by 37.5 mg to 75 mg ER daily every week

-Target dose of 225 mg ER once daily •Renal and hepatic dosing adjustments necessary

Discontinuing therapy should be done over 2 to 4 weeks
 Most common adverse effects

-Suicidal ideations [Black box warning] • Children and up to 24 years of age -Anxiety, insomnia

Painweek.

33

Duloxetine

 Initial dose: 30 mg by mouth once a day Increase dose to 60 mg ER every week -Maximum daily dose 120 mg

 Avoid use with severe renal or hepatic impairment

Discontinuing therapy should be done over 2 to 4 weeks

Most common adverse effects
 -Suicidal ideations [Black box warning]
 Children and up to 24 years of age
 -Cognitive impairment

https://online.lexi.com/lco/action/home accessed 1.10.2020

SNRI (cont'd)

- Milnacipran for fibromyalgia
 Initial dose: 12.5 mg PO once daily on Day 1
- <u>Titration schedulg:</u> 12.5 mg PO BID on Days 2-3 25 mg PO BID on Days 2-3 50 mg PO BID daily on Days 4-7 50 mg PO BID thereafter Target dose: 50 mg PO BID (100 mg/day) Maximum 100 ms 20 BID (100 mg/day) -Maximum: 100 mg PO BID (200 mg/day)
- -Dose adjustment required in renal impairment

Painweek. 34

Serotonin Syndrome

Mental status changes

- -Anxiety, agitated delirium, restlessness, disorientation Autonomic hyperactivity
- -Diaphoresis, tachycardia, hyperthermia, HTN, vomiting, and diarrhea
- Neuromuscular changes -Tremor, muscle rigidity, myoclonus, hyperreflexia, and clonus
- Severity may range from benign to lethal
 Solely a clinical diagnosis

Patient and caregiver education paramount

Painweek.

Boyer EW, et al. N Engl J Med. 2005;352(11):1112-1120.
 Mackay FJ, et al. Br J Gen Proct. 1999;49(448):871-874.

Dunkley EJ, et al. QJM. 2003;96(9):635-642.

https://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/518 accessed 1.10.2020

35

Diagnosis of SS-Hunter Criteria

- Serotonergic agent PLUS one of the following:
- -Spontaneous clonus
- -Inducible clonus and agitation or diaphoresis
- -Ocular clonus and agitation or diaphoresis
- -Tremor and hyperreflexia
- -Hypertonia
- -Temp above 38°C (100.4°F)
- Although clinical dx, consider CBC, BMP, INR, CPK, LFTs, UA, chest X-ray, head CT, to rule out differentials

Painweek.

SNRI Bleeding Risk

- Blocked serotonin uptake into platelet
 De-amplification of platelet aggregation
- Controversial data suggests:
- -Minimal risk of upper GI bleed as monotherapy -Increased risk of upper GI bleed in combination with NSAIDs

Dalton SO, et al. Arch Intern Med 2003;163(1):59-64.
 Loke YK, et al. Aliment Pharmocal Ther. 2008;27(1):31-40.
 McCloskey DJ, et al. Transl Res. 2008;151(3):166-172.
 de Abajo FJ, et al. Arch Gen Psychistry. 2008;65(7):795-803.

-Acid suppression therapy decreases risk

Painweek.

37



Painweek.

38

Lidocaine

- May be used topically or by injection Topical patch available in 0.5% to 5% •5% patch applied directly to area of postherpetic neuralgia¹ -No more than 3 patches concurrently -12 hours on, 12 hours off Trigger point injections² -Lidocaine or procaine
 - -Caution in patients on anticoagulants and local anesthetic allergy history

Kalig W.et al. Topical lidecaine for the treatment of postherpetic neuralgia. Cochrane Database Syst Rev 2007;18:CD004846.
 Alvanez DJ, et al. Trigger Points: Diagnosis and management. American Family Physician 2026 54 (9):633-634.



Antispasticity and Antispasmodic Agents

Painweek.

40




41


Muscle Relaxants

 Antispasticity agents
 Spasticity: upper motor neuron disorder characterized by muscle hypertonicity and involuntary jerks
-Multiple sclerosis, cerebral palsy, spinal cord injury
Tizanidine
Baclofen
•Diazepam

 Chou R, et al. J Pais Symptom Masage. 2004;28:140-75.
 Van Tulder HW, et al. Cochrane Database Syst Rev. 2003;(2):CD094252.

Baclofen • GABA analogue	Tizanidine • Agonist of α2 receptors (presynaptic)
 Selective GABA-B receptor agonist (↑ K+ conductance, ↓ Ca++ conductance) Muscle relaxant and analgesic (reduced) 	 Reduces adrenergic input to alpha motor neurons No effect on spinal cord reflex
substance P) • 5 mg PO TID, may titrate every 3 days to effect	Less antihypertensive effect than clonidine 2 to 8 mg PO TID
Max dose: 80 mg/day	 Max dose: 36 mg /day
Adverse effects: somnolence, increased seizure activity	 Side effects: hypotension, asthenia, elevated LFTs, hepatotoxicity







Conclusions

- Adjuvant and coanalgesics require judicious monitoring for safe use
 Extensive patient education regarding potential adverse effects is paramount
 Comorbid disease processes and concurrent medications may obscure adverse effects

Painweek.